🚨 DR. WILLIAM MAKIS MD — IVERMECTIN + FENBENDAZOLE CANCER PROTOCOL
Repurposed drugs such as ivermectin and fenbendazole are attracting growing interest among some integrative-cancer practitioners, particularly in advanced or treatment-resistant disease.
A dosing framework attributed to Dr. William Makis describes different ivermectin and fenbendazole dose ranges based on cancer severity:
💊 IVERМECTIN
Lower range: ≤0.5 mg/kg
Moderate range: ~1 mg/kg
Higher range: ~2 mg/kg
Very high range: ≥2.5 mg/kg
The framework has been promoted in connection with anecdotal reports involving advanced cancers, including reports of tumor responses and reductions in PSA.
💊 FENBENDAZOLE
222 mg: reported in some protocols several times weekly or daily
444 mg: used in some experimental protocols for advanced disease
1,000 mg/day: described as an occasional short-term regimen
Some protocols also recommend supplements such as milk thistle or curcumin and emphasize monitoring liver and kidney function.
⚠️ IMPORTANT: These are experimental/claimed protocols, not established cancer-treatment guidelines. Fenbendazole is a veterinary drug and is not approved as a cancer treatment in humans. Ivermectin is approved for certain human conditions but is not an approved cancer treatment. High doses can cause serious adverse effects and drug interactions.
The encouraging question is whether these repurposed drugs have genuine anticancer potential.
The answer requires properly designed human clinical trials—not simply testimonials, anecdotes, or dosing charts.
The research should continue.